CoChat
Sign Up
Cited by 54Dementia and Cognitive Impairment ResearchAdvanced Neuroimaging Techniques and ApplicationsCancer-related cognitive impairment studies

White matter and its relationship with cognition in subjective cognitive decline

Open access
Ohlhauser, Lisa, Parker, Ashleigh F., Smart, Colette M., Gawryluk, Jodie R., Alzheimer's Disease Neuroimaging Initiative·2019·Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
DOI 10.1016/j.dadm.2018.10.008PMC PMC6297855
Open this paper in CoChat — free accountOpen PDF

Abstract

Introduction: Subjective cognitive decline (SCD) is the earliest stage on the continuum toward Alzheimer's disease. This study examined (1) differences in white matter integrity between individuals with SCD and healthy control subjects and (2) how white matter integrity related to memory and executive function. Methods: Diffusion tensor imaging and neuropsychological assessment data were retrieved from the Alzheimer's Disease Neuroimaging Initiative database for 30 individuals with SCD and 44 control subjects. Results: Results revealed significantly lower white matter integrity in individuals with SCD relative to control subjects in widespread regions, including the bilateral corticospinal tracts, superior and inferior longitudinal fasciculi, fronto‐occipital fasciculi, corpus callosum, forceps major and minor, hippocampi, anterior thalamic radiations, and the cerebellum. There was a widespread relationship between diffusion tensor imaging metrics and executive function in SCD, but not healthy control subjects, and no relationship with memory for either group. Discussion: Relatively lower white matter integrity in SCD may be a useful early biomarker for risk of future cognitive decline. Future research should better characterize the SCD group longitudinally and in individuals at risk for Alzheimer's disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.dadm.2018.10.008

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In individuals with SCD, significantly decreased FA and increased MD have been observed in the cerebrum, mainly in the hippocampal body, entorhinal cortex and parahippocampal gyrus, uncinated fasciculi, longitudinal fasciculi and corpus callosum, whereas some studies reported no statistically significant differences in diffusion metrics.

    “In individuals with SCD, significantly decreased FA and increased MD have been observed in the cerebrum, mainly in the hippocampal body, entorhinal cortex and parahippocampal gyrus, uncinated fasciculi, longitudinal fasciculi and corpus callosum [77, 78, 109–113], whereas Kiuchi et al. and Viviano et al. reported no statistically significant differences in diffusion metrics [114, 115].”

    From Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease (2020) · cites this paper as [112]

    Split into 2 atoms — 0 confirmed, 1 partially supported, 1 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 30

  1. [3]Albert M.S. DeKosky S.T. Dickson D. Dubois B. Feldman H.H. Fox N.C. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 3 2011 270 279 PMC3312027 21514249
  2. [4]Reisberg B. Ferris S.H. de Leon M.J. Crook T. The global deterioration scale for assessment of primary degenerative Am J Psychiatry 139 1982 1136 1139 7114305
  3. [5]Reisberg B. Gauthier S. Current evidence for subjective cognitive impairment as the pre-mild cognitive impairment stage of subsequently manifest Alzheimer's disease Int Psychogeriatr 1 2008 1 16 18072981
  4. [7]Rabin L.A. Smart C.M. Amariglio R.E. Subjective cognitive decline in preclinical Alzheimer's disease Annu Rev Clin Psychol 13 2017 369 396 28482688
  5. [8]Jessen F. Amariglio R.E. van Boxtel M. Breteler M. Ceccaldi M. Chételat G. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease Alzheimers Dement 6 2014 844 852 PMC4317324 24798886
  6. [9]Smart C.M. Karr J.E. Areshenkoff C.N. Rabin L.A. Hudon C. Gates N. Non-pharmacologic interventions for older adults with subjective cognitive decline: systematic review, meta-analysis, and preliminary recommendations Neuropsychol Rev 3 2017 245 257 28271346
  7. [11]Sheikh-Bahaei N. Sajjadi S.A. Manavaki R. Gillard J.H. Imaging biomarkers in Alzheimer's disease: a practical guide for clinicians J Alzheimers Dis Rep 1 2017 71 88 30480230 PMC6159632
  8. [13]Le Bihan D. Mangin J.F. Poupon C. Clark C.A. Pappata S. Molko N. Diffusion tensor imaging: concepts and applications J Magn Reson Imaging 4 2001 534 546 11276097
  9. [14]Bosch B. Arenaza-Urquijo E.M. Rami L. Sala-Llonch R. Junqué C. Solé-Padullés C. Multiple DTI index analysis in normal aging, amnestic MCI and AD. Relationship with neuropsychological performance Neurobiol Aging 1 2012 61 74 20371138
  10. [15]Kantarci K. Fractional anisotropy of the fornix and hippocampal atrophy in Alzheimer's disease Front Aging Neurosci 6 2014 1 4 25431558 PMC4230048
  11. [17]Mayo C.D. Mazerolle E.L. Ritchie L. Fisk J.D. Gawryluk J.R. Alzheimer's Disease Neuroimaging Initiative. longitudinal changes in microstructural white matter metrics in Alzheimer's disease Neuroimage Clin 13 2017 330 338 28066707 PMC5200876
  12. [18]Amlien I.K. Fjell A.M. Diffusion tensor imaging of white matter degeneration in Alzheimer's disease and mild cognitive impairment Neuroscience 276 2014 206 215 24583036
  13. [19]Liu Y. Spulber G. Lehtimäki K.K. Könönen M. Hallikainen I. Gröhn H. Diffusion tensor imaging and tract-based spatial statistics in Alzheimer's disease and mild cognitive impairment Neurobiol Aging 9 2011 1558 1571 19913331
  14. [20]Wang Y. West J.D. Flashman L.A. Wishart H.A. Santulli R.B. Rabin L.A. Selective changes in white matter integrity in MCI and older adults with cognitive complaints Biochim Biophys Acta 3 2012 423 430 PMC3235544 21867750
  15. [21]Selnes P. Fjell A.M. Gjerstad L. Bjørnerud A. Wallin A. Due-Tønnessen P. White matter imaging changes in subjective and mild cognitive impairment Alzheimers Dement 5 2012 S112 S121 23021621
  16. [22]Selnes P. Aarsland D. Bjørnerud A. Gjerstad L. Wallin A. Hessen E. Diffusion tensor imaging surpasses cerebrospinal fluid as predictor of cognitive decline and medial temporal lobe atrophy in subjective cognitive impairment and mild cognitive impairment J Alzheimers Dis 3 2013 723 736 23186987
  17. [24]Crane P.K. Carle A. Gibbons L.E. Insel P. Mackin R.S. Gross A. Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative Brain Imaging Behav 4 2012 502 516 PMC3806057 22782295
  18. [25]Gibbons L.E. Carle A.C. Mackin R.S. Harvey D. Mukherjee S. Insel P. A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative participants with baseline mild cognitive impairment Brain Imaging Behav 4 2012 517 527 PMC3684181 22644789
  19. [26]Smith S.M. Jenkinson M. Woolrich M.W. Beckmann C.F. Behrens T.E.J. Johansen-Berg H. Advances in functional and structural MR image analysis and implementation as FSL Neuroimage 23 2004 S208 S219 15501092
  20. [27]Smith S.M. Fast robust automated brain extraction Hum Brain Mapp 3 2002 143 155 PMC6871816 12391568
  21. [28]Smith S.M. Jenkinson M. Johansen-Berg H. Rueckert D. Nichols T.E. Mackay C.E. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data NeuroImage 4 2006 1487 1505 16624579
  22. [29]Mori S. Crain B.J. MRI atlas of human white matter 2nd ed. 2006 Academic Press Amsterdam
  23. [30]Wakana S. Caprihan A. Panzenboeck M.M. Fallon J.H. Perry M. Gollub R.L. Reproducibility of quantitative tractography methods applied to cerebral white matter Neuroimage 3 2007 630 644 PMC2350213 17481925
  24. [31]Alves G.S. Oertel Knöchel V. Knöchel C. Carvalho A.F. Pantel J. Engelhardt E. Integrating retrogenesis theory to Alzheimer's disease pathology: insight from DTI-TBSS investigation of the white matter microstructural integrity Biomed Res Int 2015 2015 1 11 PMC4320890 25685779
  25. [32]Jung W.B. Lee Y.M. Kim Y.H. Mun C.-W. Automated classification to predict the progression of Alzheimer's disease using whole-brain volumetry and DTI Psychiatry Investig 1 2015 92 102 PMC4310927 25670951
  26. [33]Grambaite R. Stenset V. Reinvang I. Walhovd K.B. Fjell A.M. Fladby T. White matter diffusivity predicts memory in patients with subjective and mild cognitive impairment and normal CSF total tau levels J Int Neuropsychol Soc 1 2010 58 69 19835655
  27. [34]Valech N. Tort-Merino A. Coll-Padrós N. Olives J. León M. Rami L. Executive and language subjective cognitive decline complaints discriminate preclinical Alzheimer's disease from normal aging J Alzheimers Dis 2 2018 689 703 29254090
  28. [35]Smart C.M. Krawitz A. The impact of subjective cognitive decline on Iowa Gambling Task performance Neuropsychology 6 2015 971 987 26011116
  29. [37]Scarapicchia V. Mazerolle E.L. Fisk J.D. Ritchie L.J. Gawryluk J.R. Resting state BOLD variability in Alzheimer's disease: a marker of cognitive decline or cerebrovascular status? Front Aging Neurosci 10 2018 1 13 29515434 PMC5826397
  30. [38]De Santis S. Drakesmith M. Bells S. Assaf Y. Jones D.K. Why diffusion tensor MRI does well only some of the time: variance and covariance of white matter tissue microstructure attributes in the living human brain Neuroimage 89 2014 35 44 24342225 PMC3988851

Cited by

Sorted by citations

Authors
Ohlhauser, L., Parker, A. F., Smart, C. M., Gawryluk, J. R., & Initiative, A. D. N.
Affiliations
University of Victoria (CA)
Corresponding author
Gawryluk, Jodie R.
ORCID
Venue
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Publisher
Wiley
Published
2018-11-21
Volume
11
Issue
1
Pages
28-35
ISSN
2352-8729 (ISSN-L)
DOI
10.1016/j.dadm.2018.10.008
PMC
PMC6297855
OpenAlex
W2909661867
Cited by
54
References
7
Citations by year
2026: 1 · 2025: 8 · 2024: 15 · 2023: 4 · 2022: 7 · 2021: 10 · 2020: 5 · 2019: 4
FWCI
3.74
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UVic’s Research and Learning Repository (University of Victoria) (submittedVersion)
Funders
  • Alzheimer's Disease Neuroimaging Initiative
  • National Institutes of Health (U01 AG024904)
  • National Institute on Aging
  • National Institute of Biomedical Imaging and Bioengineering
  • AbbVie
  • Alzheimer's Association
  • Alzheimer's Drug Discovery Foundation
  • BioClinica
  • Biogen
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Genentech
  • GE Healthcare
  • H. Lundbeck A/S
  • Merck
  • Meso Scale Diagnostics
  • Novartis Pharmaceuticals Corporation
  • Pfizer
  • Takeda Pharmaceutical Company
  • Canadian Institutes of Health Research
  • Northern California Institute for Research and Education
  • University of Southern California
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced Neuroimaging Techniques and Applications
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
Keywords
subjective cognitive decline, white matter integrity, diffusion tensor imaging, executive function, memory, Alzheimer's disease, early biomarkers, corticospinal tract, corpus callosum, hippocampus, cerebellum

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review